The New Logic of Adult RSV Vaccination
Adult RSV vaccination is the subject of this series, and its important change is not simply that more vaccines are available. The decision is increasingly organized around age, underlying vulnerability, expected protection, durability, and safety. The immediate question is why current guidance recommends a dose for every adult aged 75 years or older while asking adults aged 50–74 to be considered through an increased-risk lens. Understanding that structure gives readers a better way to interpret the evidence and the practical choices that follow.
Why severe RSV changes the question
Respiratory syncytial virus is often discussed as a seasonal respiratory infection, but its consequences are not evenly distributed. In the United States, adults aged 60 years and older experience an estimated 100,000 to 150,000 RSV-associated hospitalizations and 4,000 to 8,000 deaths each year. RSV can also worsen existing heart and lung disease. For an adult whose breathing reserve is already limited, whose immune system is suppressed, or whose recovery options are constrained by frailty or care setting, an infection that might be manageable for someone else can become a hospital-level event.
That is why hospitalization is the central outcome for the adult vaccination decision. Preventing infection would matter, but the public-health value of an RSV vaccine is especially visible when it prevents respiratory failure, intensive care, or death. The question is therefore not only, “Can the vaccine block the virus?” It is also, “For whom does preventing a severe outcome matter most, and how reliably does one dose do that?”
The distinction matters because a recommendation can be broad without implying identical benefit. Age, chronic illness, immune status, and living circumstances affect the chance that RSV will become severe. They can also affect how strongly or how durably a person responds to vaccination. A useful policy has to account for both sides of that relationship: the risk of a bad outcome and the protection a dose is likely to provide.
From one age conversation to two decision paths
The current CDC guidance uses two related paths. It recommends one RSV vaccine dose for all adults aged 75 years or older. For adults aged 50–74, it recommends vaccination when the person is at increased risk of severe RSV illness. The oldest group receives an age-based recommendation because age itself is a strong marker of vulnerability. The younger group is not treated as one uniform population, so the recommendation asks for more information about health and circumstances.
Increased risk can come from chronic cardiovascular disease, chronic lung or respiratory disease, kidney failure or dialysis, certain complicated forms of diabetes, conditions that weaken airway clearance or respiratory muscles, chronic liver or blood disorders, severe obesity, or moderate or severe immune compromise. Residence in a nursing home is also included. CDC guidance allows clinical judgment to account for frailty, possible undiagnosed chronic illness, and remote or rural settings where transferring someone with severe disease to higher-level care is difficult.
This is not an exhaustive scorecard in which every condition has a fixed number of points. It is a way of recognizing that “age 60,” “age 74,” or “age 75” does not capture the whole risk profile. Two people of the same age may have very different chances of hospitalization, different consequences if they become ill, and different evidence about how well vaccination works for them. The guidance also says that patient attestation is sufficient evidence of a risk factor; lack of documentation should not become a reason to deny vaccination.
The structure can be represented simply:
This is a policy map, not a personal risk calculator. “Not in the current risk-based recommendation” does not mean “cannot become seriously ill,” and “recommended” does not mean that every person has the same absolute benefit. The map shows how guidance allocates attention: universal protection at the oldest ages, and a more context-sensitive decision for younger adults.
What risk stratification is trying to solve
Risk stratification is sometimes mistaken for a retreat from vaccination. In this setting, it is better understood as an attempt to match a recommendation to unequal stakes. If a person’s baseline risk of severe RSV is high, even an imperfect vaccine may prevent a meaningful number of serious outcomes. At the same time, if a person’s immune system is less likely to mount a durable response, the expected protection may not be identical to that seen in healthier adults. The policy has to hold both facts at once.
This also explains why a lower effectiveness estimate in a vulnerable group would not automatically make vaccination pointless. A relative percentage describes how much less often an outcome occurred compared with a relevant comparison group; it does not, by itself, describe the number of hospitalizations a person avoids. Absolute benefit depends on the underlying risk. Someone with a higher chance of hospitalization may still have substantial potential benefit even when the relative protection estimate is lower.
The reverse is also true. A strong relative estimate does not guarantee a large absolute benefit for every person if the outcome being prevented is rare in that person’s circumstances. That is one reason the current recommendation does not simply say that every adult above a single lower age should be vaccinated in the same way. The decision is linked to the serious outcome that matters, not just to the existence of a vaccine.
The evidence behind this reasoning is still being assembled. A two-season study of adults aged 60 years and older hospitalized with acute respiratory illness examined whether one dose was associated with fewer RSV-related hospitalizations. It also asked whether the result changed with immune compromise, cardiovascular or lung disease, vaccine product, RSV subtype, or time since vaccination. Those questions matter more than a single headline percentage because they test whether a population-wide result applies evenly across the people the policy is trying to protect.
Safety adds another dimension. The FDA required a Guillain-Barré syndrome warning for Abrysvo and Arexvy after postmarketing evidence suggested a possible increase in risk during the 42 days after vaccination. The agency said the evidence was not sufficient to establish causality and that the benefits of both vaccines continued to outweigh their risks. This is not a separate argument from risk stratification. It is part of the same decision: benefits, harms, uncertainty, and the population to which each estimate applies must be considered together.
The practical boundaries are deliberately modest
Current guidance does not make RSV vaccination an annual ritual. CDC recommends a single dose for the groups covered by its adult guidance, and people who have already received one dose have completed their vaccination for now. Surveillance is continuing to determine whether additional doses might be useful in the future. A possible decline in protection over time is an important question, but it is not the same as an established yearly schedule.
Timing is also more nuanced than a seasonal deadline. Eligible adults can be vaccinated at any time of year, but late summer or early fall—generally August through October in most of the continental United States—is preferred because it places protection before RSV usually begins spreading widely. A dose given at another time is not thereby declared useless. The timing recommendation is an effort to improve the chance that protection is present when exposure and severe disease are most likely.
There is no CDC preference among the three licensed adult vaccines—Arexvy, mResvia, and Abrysvo—when a vaccine is licensed and available for the eligible adult. That policy does not mean that every product has the same amount of real-world evidence in every subgroup. It means a person should not have to wait for one named product when an appropriate licensed option is available. Coadministration with other adult vaccines is permitted, although limited data suggest that giving respiratory-virus vaccines together may lower antibody titers, with unknown clinical significance, and may increase common short-term side effects. Practical considerations include the chance of returning for another visit, exposure risk, expected reactogenicity, and patient preference.
These boundaries keep the current decision grounded. They allow vaccination to address serious risk now without pretending that researchers have already settled the questions of annual revaccination, product ranking, or individualized protection.
A policy designed to learn
Adult RSV vaccination is becoming more risk-stratified because the evidence has made “older adults” too broad a category for every decision. The current framework starts with age, adds health and setting, and remains open to what real-world hospitalization data and safety monitoring reveal. It does not promise a perfectly personalized prediction, and it does not reduce health to a checklist. It offers a disciplined way to decide who should receive attention first while the evidence becomes more precise.
The next question is therefore not whether one dose works in the abstract. It is what the two-season evidence actually measured: how the study compared hospitalized adults, how its effectiveness estimate was constructed, and what protection against hospitalization and severe outcomes can—and cannot—be inferred from it.